PUBLISHER: BIS Research | PRODUCT CODE: 1650830
PUBLISHER: BIS Research | PRODUCT CODE: 1650830
Europe Liquid Biopsy Market: Focus on End User and Country - Analysis and Forecast, 2024-2033
Introduction to Europe Liquid Biopsy Market
The Europe liquid biopsy market, valued at $1.24 billion in 2024, is expected to reach $5.58 billion by 2033, exhibiting a robust CAGR of 18.18% during the forecast period 2024-2033. In Europe, liquid biopsy is a new non-invasive diagnostic technique that is transforming cancer detection and surveillance. This method has the potential to early detect cancer recurrence or evaluate treatment responses, and it provides real-time monitoring with minimal invasiveness. The growing prevalence of cancer, rising research publications, and clinical trials are some of the factors driving the growth of the liquid biopsy market. These factors are creating higher demand for liquid biopsy tests and products. More innovative and efficient tests have been developed more quickly as a result of the growing preference for minimally invasive cancer detection methods.
The market's growth has also been greatly aided by government initiatives aimed at improving cancer detection and treatment management. Because liquid biopsy products are widely accessible through a variety of distribution channels, such as online platforms and retail stores, is enhancing accessibility and ensuring a broader reach to consumers across Europe. These combined factors are helping the liquid biopsy market in Europe gain significant traction, supporting the transition to more efficient and accessible cancer detection solutions.
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2024 - 2033 |
| 2024 Evaluation | $1.24 Billion |
| 2033 Forecast | $5.58 Billion |
| CAGR | 18.18% |
Market Introduction
The market for liquid biopsies in Europe is expanding significantly as a non-invasive diagnostic technique that is revolutionizing cancer monitoring and detection. A potent substitute for conventional biopsy techniques, liquid biopsy examines blood samples for circulating tumor DNA (ctDNA), RNA, and exosomes. Its use in oncology is being fueled by its capacity to offer real-time monitoring, identify early cancer recurrence, and evaluate the effectiveness of treatment.
The growing incidence of cancer throughout Europe, the growing demand for minimally invasive diagnostic techniques, and continuous improvements in research and clinical trials are some of the factors driving this market's growth. As liquid biopsy technology advances, it supports personalized medicine strategies and allows early cancer detection at more treatable stages. Furthermore, the expansion of liquid biopsy applications extends beyond oncology, including uses in cardiology, neurology, and infectious diseases.
Government programs and regulatory assistance aimed at advancing the adoption of cutting-edge technologies and enhancing cancer diagnostics are also driving the European market. Further propelling market expansion are partnerships between academia, healthcare providers, and industry leaders, as well as increased research funding. The expansion of distribution channels, such as retail stores and internet platforms, is making liquid biopsy products more widely available to patients and healthcare providers throughout Europe.
Market Segmentation:
Segmentation 1: by End User
- Academic and Research Institutions
- Clinical Laboratories
- Pharmaceutical and Biotechnology
- Companies
- Other End Users
Segmentation 2: by Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe
How can this report add value to an organization?
Product/Innovation Strategy: The Europe liquid biopsy market has been segmented based on various categories, such as end user and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: The Europe liquid biopsy market is highly fragmented, with many smaller and private companies constantly entering the market. Key players in the liquid biopsy market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
- Dxcover Limited
- F. Hoffmann-La Roche Ltd.
- GENinCode Plc (Abcodia Ltd.)
- QIAGEN N.V.
Table of Contents
Executive Summary
Scope and Definition
1 Market
- 1.1 Market Trends
- 1.1.1 Increasing Product Launches in the Market
- 1.1.2 Growing Funding by the Key Players in the Market
- 1.2 Supply Chain Analysis: Europe Liquid Biopsy Market
- 1.3 Regulatory Framework
- 1.3.1 Regulatory Framework in the European Union (EU)
- 1.3.2 Regulation in Other Countries
- 1.4 COVID-19 Impact on Europe Liquid Biopsy Market
- 1.5 Recently Launched Product/Services
- 1.6 Reimbursement Scenario
- 1.7 Financing Scenario
- 1.7.1 Key Players Patent Portfolio
- 1.7.2 Key Players Stratification as per Raised Financing Value
- 1.7.3 Key Players Financing Analysis (by Company)
- 1.8 Product Mapping Analysis
- 1.8.1 By Technology
- 1.8.2 By Sample
- 1.8.3 By Circulating Biomarker
- 1.8.4 By Clinical Application
- 1.9 Total Addressable Market and Penetration
- 1.1 Europe Liquid Biopsy Market: Stakeholder Analysis (N=30)
- 1.10.1 Physicians' Perception
- 1.10.2 Payer's Perception
- 1.10.3 Investors' Perception
- 1.11 Liquid Biopsy Government Initiatives
- 1.12 Market Dynamics Overview
- 1.12.1 Market Drivers
- 1.12.1.1 Rising Burden of Cancer
- 1.12.1.2 Growing Research Publications and Clinical Trials in Liquid Biopsy
- 1.12.1.3 Growing Adoption and Demand of Minimally Invasive Cancer Detection Methods
- 1.12.2 Market Restraints
- 1.12.2.1 Technical Limitations in Liquid Biopsy
- 1.12.2.2 Uncertain Reimbursement and Recommendations for Liquid Biopsy Tests
- 1.12.3 Market Opportunities
- 1.12.3.1 Integration of AI in Liquid Biopsy
- 1.12.3.2 Use of Liquid Biopsy for Precision Medicine in Oncology
- 1.12.1 Market Drivers
2 Regions
- 2.1 Europe
- 2.1.1 Regional Overview
- 2.1.2 Driving Factors for Market Growth
- 2.1.3 Factors Challenging the Market
- 2.1.4 Test Volume
- 2.1.5 Market Size and Forecast
- 2.1.5.1 By End User
- 2.1.6 Germany
- 2.1.6.1 Test Volume
- 2.1.6.2 Market Size and Forecast
- 2.1.6.2.1 By End User
- 2.1.7 U.K.
- 2.1.7.1 Test Volume
- 2.1.7.2 Market Size and Forecast
- 2.1.7.2.1 End User
- 2.1.8 France
- 2.1.8.1 Test Volume
- 2.1.8.2 Market Size and Forecast
- 2.1.8.2.1 By End User
- 2.1.9 Italy
- 2.1.9.1 Test Volume
- 2.1.9.2 Market Size and Forecast
- 2.1.9.2.1 By End User
- 2.1.10 Spain
- 2.1.10.1 Test Volume
- 2.1.10.2 Market Size and Forecast
- 2.1.10.2.1 By End User
- 2.1.11 Rest-of-Europe
- 2.1.11.1 Test Volume
- 2.1.11.2 Market Size and Forecast
- 2.1.11.2.1 By End User
3 Markets - Competitive Benchmarking & Company Profiles
- 3.1 Company Profiles
- 3.1.1 Dxcover Limited
- 3.1.1.1 Overview
- 3.1.1.2 Top Products
- 3.1.1.3 Top Competitors
- 3.1.1.4 Key Personnel
- 3.1.1.5 Analyst View
- 3.1.2 F. Hoffmann-La Roche Ltd.
- 3.1.2.1 Overview
- 3.1.2.2 Top Products
- 3.1.2.3 Top Competitors
- 3.1.2.4 Key Personnel
- 3.1.2.5 Analyst View
- 3.1.3 GENinCode PLC (Abcodia Ltd.)
- 3.1.3.1 Overview
- 3.1.3.2 Top Products
- 3.1.3.3 Top Competitors
- 3.1.3.4 Key Personnel
- 3.1.3.5 Analyst View
- 3.1.4 QIAGEN N.V.
- 3.1.4.1 Overview
- 3.1.4.2 Top Products
- 3.1.4.3 Top Competitors
- 3.1.4.4 Key Personnel
- 3.1.4.5 Analyst View
- 3.1.1 Dxcover Limited
4 Research Methodology
- 4.1 Data Sources
- 4.1.1 Primary Data Sources
- 4.1.2 Secondary Data Sources
- 4.1.3 Data Triangulation
- 4.2 Market Estimation and Forecast
List of Figures
- Figure 1: Europe Liquid Biopsy Market, $Million, 2024, 2028, and 2033
- Figure 2: Liquid Biopsy Market (by Region), $Million, 2023, 2027, and 2033
- Figure 3: Key Events to Keep Track of in the Liquid Biopsy Market
- Figure 4: Impact of COVID-19 on Liquid Biopsy Market
- Figure 5: Patent Published (by Country), January 2021-May 2024
- Figure 6: Number of Liquid Biopsy Patents (by Year), January 2021-May 2024
- Figure 7: Financing Analysis (by Latest Deal Amount), $Million, FY2023-2024
- Figure 8: Europe Liquid Biopsy Market Scenario, 2023
- Figure 9: Frequently Used Technology in Liquid Biopsy
- Figure 10: Most Important Factors for Adoption of NGS-Based Liquid Biopsy
- Figure 11: Treatment Guidelines for Treatment of Cancer Patients
- Figure 12: Major Challenges Faced While Performing Liquid Biopsy
- Figure 13: Average Cost of Technologies for the Europe Liquid Biopsy Market (N=30 )
- Figure 14: Cost Difference Across Different End Users for the Europe Liquid Biopsy Market
- Figure 15: Key Factors for Determining Reimbursement Possibility for the Europe Liquid Biopsy Market
- Figure 16: Estimated Global Cancer Incidence in 2020 and 2040
- Figure 17: Estimated New Cancer Cases (2022-2045): Both Sexes, Ages 0-85
- Figure 18: Upsurge in Research Publications in Liquid Biopsy, 2015-2023
- Figure 19: Comparison of Liquid Biopsy vs. Tissue Biopsy
- Figure 20: Europe Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
- Figure 21: Europe Liquid Biopsy Market, $Million, 2023-2033
- Figure 22: Germany Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
- Figure 23: Germany Liquid Biopsy Market, $Million, 2023-2033
- Figure 24: U.K. Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
- Figure 25: U.K. Liquid Biopsy Market, $Million, 2023-2033
- Figure 26: France Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
- Figure 27: France Liquid Biopsy Market, $Million, 2023-2033
- Figure 28: Italy Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
- Figure 29: Italy Liquid Biopsy Market, $Million, 2023-2033
- Figure 30: Spain Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
- Figure 31: Spain Liquid Biopsy Market, $Million, 2023-2033
- Figure 32: Rest-of-Europe Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
- Figure 33: Data Triangulation
- Figure 34: Top-Down and Bottom-Up Approach
- Figure 35: Assumptions and Limitations
List of Tables
- Table 1: Market Snapshot
- Table 2: Liquid Biopsy Market, Market Opportunities
- Table 3: Product Launches, January 2021-April 2024
- Table 4: Some of the Strategic Funding, January 2022-April 2024
- Table 5: Launched Liquid Biopsy Tests from Players in the Liquid Biopsy Market
- Table 6: Reimbursement Scenario for Key Players' Offerings in the Liquid Biopsy Market
- Table 7: Europe Liquid Biopsy Market: Key Players Patent Portfolio
- Table 8: Liquid Biopsy Product Mapping Analysis (by Technology)
- Table 9: Liquid Biopsy Product Mapping Analysis (by Sample)
- Table 10: Liquid Biopsy Product Mapping Analysis (by Circulating Biomarker)
- Table 11: Liquid Biopsy Product Mapping Analysis (by Clinical Application)
- Table 12: Government Initiatives for Liquid Biopsies
- Table 13: Impact Analysis of Market Navigating Factors, 2023-2033
- Table 14: Liquid Biopsy Market (by Region), $Million, 2023-2033
- Table 15: Europe Liquid Biopsy Market (by End User), $Million, 2023-2033
- Table 16: Germany Liquid Biopsy Market (by End User), $Million, 2023-2033
- Table 17: U.K. Liquid Biopsy Market (by End User), $Million, 2023-2033
- Table 18: France Liquid Biopsy Market (by End User), $Million, 2023-2033
- Table 19: Italy Liquid Biopsy Market (by End User), $Million, 2023-2033
- Table 20: Spain Liquid Biopsy Market (by End User), $Million, 2023-2033
- Table 21: Rest-of-Europe Liquid Biopsy Market, $Million, 2023-2033
- Table 22: Rest-of-Europe Liquid Biopsy Market (by End User), $Million, 2023-2033
